United Therapeutics Corp (UTHR) Stock Price & Analysis

United Therapeutics Corp (UTHR) fell 0.54% to USD 487.61 as of September 8, 2026 at 05:46 UTC, according to Nexqual real-time market data.

UTHR last closed at USD 487.61; the session ranged USD 484.33–494.09 on volume of 327,024 shares. Market capitalization is —, with a 52-week range of USD 392.17–609.35 (NMS). Source: Nexqual, September 8, 2026 at 05:46 UTC.

Key Statistics (as of September 8, 2026 at 05:46 UTC)

Technical Analysis (UTHR)

Nexqual's technical model rates UTHR "SELL" based on 2 bullish and 5 bearish signals across 128 daily candles, as of September 8, 2026 at 05:46 UTC.

From United Therapeutics Corp's Latest SEC 10-K Filing (filed 2026-02-25)

Key Strengths & Strategy (as disclosed to the SEC)

• Nebulized Tyvaso is administered four times a day using our proprietary Tyvaso Inhalation System, which consists of an ultrasonic nebulizer and related accessories.
• Nebulized Tyvaso is regulated by the FDA as a drug-device combination product approved under an NDA consisting of Tyvaso drug product and the Tyvaso Inhalation System.
• Ex Vivo Lung Perfusion Our ex vivo lung perfusion ( EVLP ) program uses the first FDA-approved acellular EVLP technology on the market, the XVIVO Perfusion System ( XPS ™) with Steen Solution™ Perfusate, to offer the only commercially-available centralized EVLP service in the United States.
• In 2024, Lung Bioengineering completed a registrational study of another centralized EVLP technology called the Centralized Lung Evaluation System ( CLES ) and submitted a premarket approval application to the FDA in September 2024 for commercial approval of CLES, which is under review by the FDA.

Partnerships

• Under our agreement with 3D Systems, we also have the exclusive right to develop additional human solid organ alternatives using 3D Systems' printing technology. • IVIVA .
• Remunity and RemunityPRO Pumps In February 2021, we launched commercial sales of the Remunity Pump, which is a semi-disposable system for subcutaneous delivery of treprostinil that we developed in collaboration with DEKA Research & Development Corp. ( DEKA ) under an exclusive development and license agreement.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 05:46 UTC. This page is informational and not investment advice.